Apimeds Pharmaceuticals US (APUS) Prepaid Assets (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Prepaid Assets for 4 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Prepaid Assets rose 38.52% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $2.2 million (up 38.52% YoY), and the FY2025 full-year result was $2.3 million, up 23839.85% from the prior year.
• Prepaid Assets retreated to $2.2 million in Q2 2026 per APUS's latest filing, from $2.3 million in the prior quarter.
• Across five years, Prepaid Assets topped out at $2.3 million in Q4 2025 and bottomed at $9562.0 in Q1 2025.
• Historically, Prepaid Assets has averaged $1.2 million across 4 years, with a median of $1.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Prepaid Assets fell 17.19% in 2024, then jumped 23839.85% in 2025.
• Over 4 years, Prepaid Assets stood at $11595.0 in 2023, then dropped by 17.19% to $9602.0 in 2024, then surged by 23839.85% to $2.3 million in 2025, then declined by 2.73% to $2.2 million in 2026.
• According to Business Quant data, Prepaid Assets over the past three periods registered $2.2 million, $2.3 million, and $2.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.